Advertisement

Topics

Alexion Pharmaceuticals Inc. (ALXN) Downgraded by Vetr Inc. to "Strong Sell"

02:08 EDT 19 Oct 2016 | Topix

They currently have a $107.00 price objective on the biopharmaceutical company's stock. Vetr 's price target points to a potential downside of 11.86% from the company's previous close.

Original Article: Alexion Pharmaceuticals Inc. (ALXN) Downgraded by Vetr Inc. to "Strong Sell"

NEXT ARTICLE

More From BioPortfolio on "Alexion Pharmaceuticals Inc. (ALXN) Downgraded by Vetr Inc. to "Strong Sell""

Quick Search
Advertisement
 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...